In vitro and in vivo preclinical models have demonstrated enhanced anti-tumour effects when both pathways are targeted simultaneously.8 Therefore, combination therapy with drugs targeting the MAPK and PI3K signalling pathways is predicted to improve efficacy compared with inhibition of either cascade alone and may be an effective therapeutic strategy in the treatment of a variety of cancers. The gene discussed is PIK3CA; the disease is neoplasm.